NASDAQ:NTRB Nutriband 5/30/2025 Earnings Report $7.26 -0.92 (-11.25%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$7.63 +0.37 (+5.04%) As of 06/5/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Nutriband EPS ResultsActual EPS-$0.12Consensus EPS -$0.13Beat/MissBeat by +$0.01One Year Ago EPSN/ANutriband Revenue ResultsActual Revenue$0.67 millionExpected Revenue$0.71 millionBeat/MissMissed by -$40.00 thousandYoY Revenue GrowthN/ANutriband Announcement DetailsQuarterDate5/30/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Nutriband Earnings HeadlinesNutriband (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl DevelopmentJune 4 at 9:35 AM | theglobeandmail.comNutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity ConferenceJune 3 at 9:53 AM | finance.yahoo.comTrump’s Strange “Midnight Tweet” Could Trigger Massive GainsPresident Trump sends out explosive tweets at all hours of the day... And the market reacts violently. According to one Wall Street legend, Americans can target as much as 627% within HOURS. You have to see how to target these massive profits (from Trump’s latest tweets) for yourself....June 6, 2025 | Monument Traders Alliance (Ad)Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA FentanylJune 2, 2025 | finance.yahoo.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Gareth Sheridan, CEO of Nutriband Inc.May 27, 2025 | finance.yahoo.comNutriband (NASDAQ: NTRB) Charts Path to CommercializationMay 24, 2025 | theglobeandmail.comSee More Nutriband Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nutriband? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nutriband and other key companies, straight to your email. Email Address About NutribandNutriband (NASDAQ:NTRB) develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.View Nutriband ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Red Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode DealCrowdStrike Stock Slips: Analyst Downgrades Before Earnings Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Upcoming Earnings Haleon (6/11/2025)Oracle (6/11/2025)Adobe (6/12/2025)Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)PepsiCo (7/10/2025)Bank of America (7/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
